The Cost-Effectiveness of Dapagliflozin (Forxiga®) Versus Glipizide in the Treatment of Type 2 Diabetes Mellitus (T2DM) in England and Wales
Nov 1, 2013, 00:00
10.1016/j.jval.2013.08.677
https://www.valueinhealthjournal.com/article/S1098-3015(13)02582-5/fulltext
Title :
The Cost-Effectiveness of Dapagliflozin (Forxiga®) Versus Glipizide in the Treatment of Type 2 Diabetes Mellitus (T2DM) in England and Wales
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)02582-5&doi=10.1016/j.jval.2013.08.677
First page :
A441
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
652